ArticleTherapeutic drug monitoring2026
Improvements, Challenges, and the Investigation of Two Unknowns in Arsenic Urine Speciation Analysis by HPLC-ICP-MS: From Development to Post-implementation.
Article in Therapeutic drug monitoring, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-performance liquid chromatography-inductively coupled plasma mass spectrometry (HPLC-ICP-MS) is a critical analytical technique for determining the different forms of arsenic present in human urine. A new method was developed to overcome the shortcomings, such as poor resolution between critical arsenic species, of previously validated methods. The goal was to achieve resolution between 6 arsenic species that can be present in urine, including 2 common nontoxic organic species (arsenobetaine [AsB] and arsenocholine [AsC]), 2 methylated species with intermediate toxicity (monomethylarsonic acid [MMA] and dimethylarsinic acid [DMA]), and toxic inorganic forms (arsenous acid [AsIII] and arsenic acid [AsV]). In addition, efforts have been focused on identifying 2 unknown arsenic peaks present in approximately 5% of the patient population.
methodsHPLC-ICP-MS was developed using an anion-exchange analytical column with upfront dilution of urine samples. Some samples were reinjected into a high-performance liquid chromatography quadrupole time-of-flight tandem mass spectrometer (QTOF-MS) to identify the unknown compounds.
resultsThe newly developed method achieved adequate resolution for 6 known arsenic species. The method was successfully validated after additional challenges, such as stabilizing the transformation of certain arsenic species (AsB and AsIII), were resolved. A retrospective analysis of 3050 urine samples revealed positivity rates of 79.1% and 54.7% for AsB and DMA, respectively. All the other species were detected ≤2% of the time. Two unknown arsenic species analyzed by HPLC-QTOF-MS were identified as dimethylarsinoyl acetic acid (DMAA), a possible arsenosugar metabolite, and p-arsanilic acid (ASA), a likely contaminant from preanalytical exposure to urinalysis test strips.
conclusionsThis new method improves the reliability of arsenic speciation analysis in urine, benefiting both clinical laboratories and patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.